200 related articles for article (PubMed ID: 31801945)
1. USP22-dependent HSP90AB1 expression promotes resistance to HSP90 inhibition in mammary and colorectal cancer.
Kosinsky RL; Helms M; Zerche M; Wohn L; Dyas A; Prokakis E; Kazerouni ZB; Bedi U; Wegwitz F; Johnsen SA
Cell Death Dis; 2019 Dec; 10(12):911. PubMed ID: 31801945
[TBL] [Abstract][Full Text] [Related]
2. USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity.
Kosinsky RL; Zerche M; Saul D; Wang X; Wohn L; Wegwitz F; Begus-Nahrmann Y; Johnsen SA
Cell Death Differ; 2020 Apr; 27(4):1328-1340. PubMed ID: 31527800
[TBL] [Abstract][Full Text] [Related]
3. Knock-down of ubiquitin-specific protease 22 by micro-RNA interference inhibits colorectal cancer growth.
Xu H; Liu YL; Yang YM; Dong XS
Int J Colorectal Dis; 2012 Jan; 27(1):21-30. PubMed ID: 21773699
[TBL] [Abstract][Full Text] [Related]
4. UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib.
Landmann H; Proia DA; He S; Ogawa LS; Kramer F; Beißbarth T; Grade M; Gaedcke J; Ghadimi M; Moll U; Dobbelstein M
Cell Death Dis; 2014 Sep; 5(9):e1411. PubMed ID: 25210794
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic effects of inhibition of heat shock protein 90 (HSP90) in human pancreatic and colon cancer.
Nagaraju GP; Wu C; Merchant N; Chen Z; Lesinski GB; El-Rayes BF
Cancer Lett; 2017 Aug; 402():110-116. PubMed ID: 28583846
[TBL] [Abstract][Full Text] [Related]
6. Heat shock protein 90 promotes epithelial to mesenchymal transition, invasion, and migration in colorectal cancer.
Nagaraju GP; Long TE; Park W; Landry JC; Taliaferro-Smith L; Farris AB; Diaz R; El-Rayes BF
Mol Carcinog; 2015 Oct; 54(10):1147-58. PubMed ID: 24861206
[TBL] [Abstract][Full Text] [Related]
7. HSP90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy.
Nagaraju GP; Alese OB; Landry J; Diaz R; El-Rayes BF
Oncotarget; 2014 Oct; 5(20):9980-91. PubMed ID: 25296971
[TBL] [Abstract][Full Text] [Related]
8. Is co-expression of USP22 and HSP90 more effective in predicting prognosis of gastric cancer?
Zheng H; Yu J; Li W; Yang D; Gao C; Zhang Q; Xu L
Pathol Res Pract; 2019 Apr; 215(4):653-659. PubMed ID: 30598339
[TBL] [Abstract][Full Text] [Related]
9. [Role of ubiquitin-specific peptidase 22 in multidrug resistance of colorectal cancer and its correlation with multidrug resistance gene P-gp].
Zhang L; Wang JY; Li X; Chen XY; Wu WX
Zhonghua Yi Xue Za Zhi; 2021 Dec; 101(48):3944-3949. PubMed ID: 34954996
[No Abstract] [Full Text] [Related]
10. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Jiang J; Lu Y; Li Z; Li L; Niu D; Xu W; Liu J; Fu L; Zhou Z; Gu Y; Xia F
Invest New Drugs; 2017 Jun; 35(3):251-259. PubMed ID: 28111726
[TBL] [Abstract][Full Text] [Related]
11. USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer.
Wang S; Zhong X; Wang C; Luo H; Lin L; Sun H; Sun G; Zeng K; Zou R; Liu W; Sun N; Song H; Liu W; Zhang Q; Liao Z; Teng X; Zhou T; Sun X; Zhao Y
Cell Death Differ; 2020 Nov; 27(11):3131-3145. PubMed ID: 32494025
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitin-Specific Protease 22/Silent Information Regulator 1 Axis Plays a Pivotal Role in the Prognosis and 5-Fluorouracil Resistance in Hepatocellular Carcinoma.
Wen X; Ling S; Wu W; Shan Q; Liu P; Wang C; Wei X; Ding W; Teng X; Xu X
Dig Dis Sci; 2020 Apr; 65(4):1064-1073. PubMed ID: 31587155
[TBL] [Abstract][Full Text] [Related]
13. FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism.
Acquaviva J; He S; Zhang C; Jimenez JP; Nagai M; Sang J; Sequeira M; Smith DL; Ogawa LS; Inoue T; Tatsuta N; Knowles MA; Bates RC; Proia DA
Mol Cancer Res; 2014 Jul; 12(7):1042-54. PubMed ID: 24784839
[TBL] [Abstract][Full Text] [Related]
14. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of ubiquitin-specific protease 22 can promote cancer progression and predict therapy failure in human colorectal cancer.
Liu YL; Yang YM; Xu H; Dong XS
J Gastroenterol Hepatol; 2010 Nov; 25(11):1800-5. PubMed ID: 21039844
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of USP22 reduces cell stemness and enhances the sensitivity of pancreatic cancer cells to cisplatin by inactivating the Wnt/β-catenin pathway.
Li Z; Huang X; Hu W; Lu H
Tissue Cell; 2022 Aug; 77():101787. PubMed ID: 35623308
[TBL] [Abstract][Full Text] [Related]
17. The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma.
Bai Z; Du Y; Cong L; Cheng Y
Gene; 2020 Oct; 758():144960. PubMed ID: 32687947
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling.
Liu H; Liu N; Zhao Y; Zhu X; Wang C; Liu Q; Gao C; Zhao X; Li J
Aging (Albany NY); 2019 Nov; 11(21):9643-9660. PubMed ID: 31689236
[TBL] [Abstract][Full Text] [Related]
19. USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response.
Prokakis E; Dyas A; Grün R; Fritzsche S; Bedi U; Kazerouni ZB; Kosinsky RL; Johnsen SA; Wegwitz F
Oncogene; 2021 Jun; 40(23):4004-4018. PubMed ID: 34007022
[TBL] [Abstract][Full Text] [Related]
20. USP22 drives colorectal cancer invasion and metastasis via epithelial-mesenchymal transition by activating AP4.
Li Y; Yang Y; Li J; Liu H; Chen F; Li B; Cui B; Liu Y
Oncotarget; 2017 May; 8(20):32683-32695. PubMed ID: 28427243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
